Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Cell Therapeutics, Inc. Patents
Assignee:
Cell Therapeutics, Inc.
Address:
Seattle, WA
No. of patents:
94
Patents:


1 2










Patent Number Title Of Patent Date Issued
8129348 Conjugates of biologically active proteins having a modified in vivo half-life March 6, 2012
Disclosed are biologically active protein conjugates that comprise a biologically active polypeptide coupled via a peptide bond to a polypeptide comprising from 2 to about 500 units of a repeating peptide motif, wherein the biologically active protein conjugate exhibits a modified pl
7618968 Aryl triazines as LPAAT-.beta. inhibitors and uses thereof November 17, 2009
The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase .beta. (LPAAT-.beta.) activity and/or proliferation of cells such as tumor cells.
7608620 LPAAT-.beta. inhibitors and uses thereof October 27, 2009
The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase .beta. (LPAAT-.beta.) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-.bet
7419984 Pyrimidines and uses thereof September 2, 2008
The invention relates to pyrimidines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase .beta. (LPAAT-.beta.) activity and/or proliferation of cells such as tumor-cells.
7399860 Manufacture of polyglutamate-therapeutic agent conjugates July 15, 2008
The invention provides new processes for preparing polyglutamic acid-therapeutic agent conjugates for clinical development and pharmaceutical use, and polyglutamic acid-therapeutic agent conjugates prepared by these processes.
7291616 Aryl triazines as LPAAT-.beta. inhibitors and uses thereof November 6, 2007
The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase .beta. (LPAAT-.beta.) activity and/or proliferation of cells such as tumor cells.
7247630 Uses of tricyclic compounds July 24, 2007
Novel tricyclic compounds are disclosed having the general structure of Formulas I or II: ##STR00001## were R1, R2 and R3 are defined in the written description of the invention. The compounds are useful for the treatment or prevention of symptoms or manifestations associated with d
7208507 Pyridines and uses thereof April 24, 2007
The invention relates to pyridines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase .beta. (LPAAT-.beta.) activity and/or proliferation of cells such as tumor cells.
7173041 Polyglutamic acid-camptothecin conjugates and methods of preparation February 6, 2007
The invention provides polyglutamic acid-therapeutic agent conjugates and methods for their preparation and use.
7153864 Polyglutamic acid-camptothecin conjugates and methods of preparation December 26, 2006
The invention provides polyglutamic acid-therapeutic agent conjugates and methods for their preparation and use.
7135314 Human phosphatidic acid phosphatase November 14, 2006
This invention relates to a biotechnology invention concerning human phosphatidic acid phosphatase. More particularly, this invention relates to three variants of human phosphatidic acid phosphatase namely PAP-.alpha.(1 and 2), PAP-.beta. and PAP-.gamma. and uses thereof.
7064125 LPAAT-.beta. inhibitors and uses thereof June 20, 2006
The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase .beta. (LPAAT-.beta.) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-.bet
7053096 Compounds having selective hydrolytic potentials May 30, 2006
Disclosed are compounds having selective hydrolytic potential. The disclosed compounds are useful as compounds having selective stability and are capable of undergoing programmed hydrolysis in biologic systems.
7052891 Human lysophoshatidic acid acyltransferase gamma-1 polypeptide May 30, 2006
Polypeptides are obtained, for example, via expression of encoding cDNA sequences, that have the activity of the enzyme lysophosphatidic acid acyltransferase (LPAAT), also known as 1-acyl sn-glycerol-3-phosphate acyltransferase.
7045327 Human lysophosphatidic acid acyltransferase gamma-2 polypeptide May 16, 2006
Polypeptides are obtained, for example, via expression of encoding cDNA sequences, that have the activity of the enzyme lysophosphatidic acid acyltransferase (LPAAT), also known as 1-acyl sn-glycerol-3-phosphate acyltransferase.
6878715 Therapeutic compounds for inhibiting interleukin-12 signals and method for using same April 12, 2005
Novel heterocyclic compounds having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations associated with disorders affected by Interleukin-12 ("IL-12") intracellular signaling, such as,
6875781 Pyridines and uses thereof April 5, 2005
The invention relates to pyridines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase .beta. (LPAAT-.beta.) activity and/or proliferation of cells such as tumor cells.
6825180 Pyridopyrimidine compounds and their uses November 30, 2004
Novel pyridopyrimidine-based compounds are found to be useful for the treatment or prevention of symptoms or manifestations associated with diseases or disorders affected by cytokine intracellular signaling.
6780865 Compounds having selective hydrolytic potentials August 24, 2004
Disclosed are compounds having selective hydrolytic potential. The disclosed compounds are useful as compounds having selective stability and are capable of undergoing programmed hydrolysis in biologic systems. The disclosed compounds have a structure of formula I: ##STR1##
6774130 Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same August 10, 2004
Novel heterocyclic compounds having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations associated with disorders affected by Interleukin-12 ("IL-12") intracellular signaling, such as,
6693105 Hydroxyl-containing compounds February 17, 2004
Disclosed are therapeutic compounds having the formula:including resolved enantiomers, diastereomers, hydrates, salts, solvates or mixtures thereof where j is an integer from one to three. The core moiety is a bicyclic ring structure having at least one heterocyclic ring that contains fi
6670143 Method of screening compounds that inhibit lysophosphatidic acid acyltransferase December 30, 2003
Polypeptides are obtained, for example, via expression of encoding cDNA sequences, that have the activity of the enzyme lysophosphatidic acid acyltransferase (LPAAT), also known as 1-acyl sn-glycerol-3-phosphate acyltransferase.
6638938 Method for preventing tissue injury from hypoxia October 28, 2003
There is disclosed a method for preventing tissue injury caused by tissue hypoxia and reoxygenation, comprising administering a compound that inhibits signal transduction by inhibiting cellular accumulation of linoleoyl phosphatidic acid (PA) through an inhibition of the enzyme LPAAT
6586429 Tricyclic fused xanthine compounds and their uses July 1, 2003
Novel tricyclic compounds are found to be useful for the treatment or prevention of symptoms or manifestations associated with diseases or disorders affected by cytokine intracellular signaling. The compounds have the following formulas ##STR1##where R.sub.1, R.sub.2 and R.sub.3 are
6503700 Mammalian CDP-diacylglycerol synthase January 7, 2003
There is disclosed cDNA sequences and polypeptides having the enzyme CDP-diacylglycerol synthase (CDS) activity. CDS is also known as CTP:phosphatidate cytidylyltransferase. There is further disclosed methods for isolation and production of polypeptides involved in phosphatidic acid
6469017 Method of inhibiting interleukin-12 signaling October 22, 2002
A method for blocking IL-12 signaling by administration of the following compound: ##STR1##wherein, R.sub.1 is H, CH.sub.3, sulfate, phosphate, or salt thereof; R.sub.2 is alkyl (C.sub.1-12), alkoxyalkyl (C.sub.1-11), dialkoxyalkyl, CH.sub.2 C.sub.6 H.sub.5, --CH.sub.2 -furan, biotin
6331254 Methods of separation and detection December 18, 2001
Methods which employ thin layer chromatography for separating and detecting hydrophobic target molecules are particularly useful in separating biologically relevant lipids. By utilizing non-destructive detection techniques, these methods also can be adapted to further quantification or
6316458 Method of enhancing insulin action November 13, 2001
A category of hydroxyalkyl-substituted xanthines are useful in treating patients suffering from disorders associated with impaired glucose metabolism or impaired insulin function. Use of these compounds, for example, restores insulin responsiveness in otherwise insulin-resistant Type
6274363 Phosphatidylcholine phospholipase D August 14, 2001
Three new isoforms of phosphatidylcholine phospholipase D, hPLD2.1, hPLD2.2 and hPLD1.5, can be produced recombinantly and are useful for screening compounds, as drug candidates, for an ability to modify PCPLD activity.
6200769 Mammalian CDP-diacylglycerol synthase March 13, 2001
There is disclosed cDNA sequences and polypeptides having the enzyme CDP-diacylglycerol synthase (CDS) activity. CDS is also known as CTP:phosphatidate cytidylyltransferase. There is further disclosed methods for isolation and production of polypeptides involved in phosphatidic acid
6136964 Mammalian lysophosphatidic acid acyltransferase October 24, 2000
There is disclosed cDNA sequences and polypeptides having the enzyme lysophosphatidic acid acyltransferase (LPAAT) activity. LPAAT is also known as 1-acyl sn-glycerol-3-phosphate acyltransferase.
6133274 Hydroxyl-containing bicyclic compounds October 17, 2000
Disclosed are therapeutic compounds having the formula:including resolved enantiomers, diastereomers, hydrates, salts, solvates and mixtures thereof. j is an integer from one to three, the core moiety is either non-cyclic or comprises at least one five- to seven-membered ring structure,
6121270 Epoxide-containing compounds September 19, 2000
Disclosed are enantiomers diastereomers, salts, solvates, hydrates and mixtures thereof, of formula I: ##STR1## The core moiety is non-cyclic or at least one five- to seven-membered ring, n is an integer from about 4 to about 16, R.sub.1 and R.sub.2 are hydrogen, halogen or C.sub
6103730 Amine substituted compounds August 15, 2000
Compounds and pharmaceutical compositions, including resolved enantiomers and/or diastereomers, hydrates, salts, solvates and mixtures thereof, have the formula:In these compounds, j is an integer from one to three; the core moiety is a cyclic core, the cyclic core being non-cyclic or at
6100271 Therapeutic compounds containing xanthinyl August 8, 2000
Therapeutic compounds with at least one carboxylic acid, ester or amide-substituted side chain have the formula:wherein j is an integer from one to three. The core moiety is non-cyclic or cyclic (carbocyclic or heterocyclic). R may be selected from among hydrogen, halogen, hydroxyl, amin
6075029 Xanthine modulators of metabolism of cellular P-450 June 13, 2000
A new class of xanthine compounds, variously substituted at the 1, 3, 7 and 8 positions, is characterized by an ability to modulate the activity of key enzymes involved in drug metabolism. These compounds generally are useful in affecting drug metabolism and, particularly, in extending t
6060263 Mammalian lysophosphatidic acid acyltransferase May 9, 2000
There is disclosed cDNA sequences and polypeptides having the enzyme lysophosphatidic acid acyltransferase (LPAAT) activity. LPAAT is also known as 1-acyl sn-glycerol-3-phosphate acyltransferase.
6057328 Method for treating hyperoxia May 2, 2000
Disclosed are methods for treating conditions resulting from hyperoxia or mechanical ventilation comprising the administration of a compound of the formula: ##STR1## wherein R.sub.1 is a substantially pure resolved R enantiomer .omega.-1, secondary alcohol-substituted (C.sub.5-8)
6043250 Methods for using therapeutic compounds containing xanthinyl March 28, 2000
Therapeutic compounds with at least one carboxylic acid, ester or amide-substituted side chain have the formula:wherein j is an integer from one to three. The core moiety is non-cyclic or cyclic (carbocyclic or heterocyclic). R may be selected from among hydrogen, halogen, hydroxyl, amin
6020337 Electronegative-substituted long chain xanthine compounds February 1, 2000
Therapeutic compounds, including resolved enantiomers and/or diastereomers, hydrates, salts, solvates and mixtures thereof, having a formula: ##STR1## wherein R.sub.0 is selected from the group consisting of hydrogen, halo, hydroxyl, amino, substituted or unsubstituted C.sub.(1-10) a
5985926 Method for inhibiting intracellular viral replication November 16, 1999
There is disclosed a method of preventing or delaying the occurrence of acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus (HIV) seropositive humans by administering an effective amount of a compound that inhibits cellular signaling through a specific phospholi
5965564 Enantiomerically pure hydroxylated xanthine compounds October 12, 1999
There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modula
5955624 Growth stimulating factors September 21, 1999
Alk-1-enyl glycerol derivatives and method of preparing same. The derivatives stimulate cell and tissue growth.
5952480 Mammalian CDP-diacylglycerol synthase September 14, 1999
There is disclosed cDNA sequences and polypeptides having the enzyme CDP-diacylglycerol synthase (CDS) activity. CDS is also known as CTP:phosphatidate cytidylytransferase. There is further disclosed methods for isolation and production of polypeptides involved in phosphatidic acid m
5929081 Method for treating diseases mediated by cellular proliferation in response to PDGF, EGF, FGF an July 27, 1999
There is disclosed a method for:(1) inhibiting new blood vessel formation that is useful for treating or preventing progression of diabetic retinopathy, cavernous haemangiomas, Kaposi's sarcoma, tumors composed of endothelial-like cells, and growth of cancer cells by preventing their dev
5889011 Substituted amino alkyl compounds March 30, 1999
Compounds and pharmaceutical compositions thereof comprise the formula:including resolved enantiomers and/or diastereomers, hydrates, salts, solvates and mixtures thereof, wherein J is an integer from one to three, the core moiety is non-cyclic or comprises at least one, five- to seven-m
5866576 Epoxide-containing compounds February 2, 1999
Disclosed are enantiomers, diastereomers, salts, solvates, hydrates and mixtures thereof, of formula I: ##STR1## The core moiety is a monocyclic ring structure having five to six ring atoms and two nitrogen atoms at the 1 and 3 positions, n is an integer from 4 to 16, R.sub.1 and
5859222 Human phosphatidylcholine phospholipase D January 12, 1999
Disclosed are human cDNA and polypeptides sequences having phosphatidylcholine phospholipase D (PCPLD).
5859018 Method for treating diseases mediated by cellular proliferation in response to PDGF, EGF, FGF, a January 12, 1999
There is disclosed a method for:(1) inhibiting new blood vessel formation that is useful for treating or preventing progression of diabetic retinopathy, cavernous haemangiomas, Kaposi's sarcoma, tumors composed of endothelial-like cells, and growth of cancer cells by preventing their dev
5859017 Method for inhibiting mast cell and basophil activation January 12, 1999
In a method for treating or preventing allergy or allergic disorders an effective amount of a compound that inhibits intracellular generation of phosphatidic acid and diacylglycerol is administered. The intracellular generation of phosphatidic acid and diacylglycerol results from allerge
1 2

 
 
  Recently Added Patents
Blow moulding machine with compressed air recycling
Solid state lighting circuit and controls
Light modulators and optical apparatuses including the same
Sheet member and method of manufacturing sheet member
Range extension techniques for a wireless local area network
Droplet generation and detection device, and droplet control device
Denial of service (DoS) attack prevention through random access channel resource reallocation
  Randomly Featured Patents
Fluid loss control additives for oil well cementing compositions
Imidazodiazepine derivatives
Device for sealing envelopes made of plastic
Photographic cyan coupler
Multiplex amplification of short tandem repeat loci
Method and apparatus for levator distension repair
Method and system for discovering managed systems in a network
Device for the automatic detection and inspection of defects on a running web, such as a textile fabric
Rotating rod, rotating press roll nip coating apparatus
Lean NO.sub.x catalyst/trap method